Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
4 "Kyungbin Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Case Study
Primary hepatic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
Soyeon Choi, Ji Hye Kim, Kyungbin Kim, Misung Kim, Hye Jeong Choi, Young Min Kim, Jae Hee Suh, Min Jung Seo, Hee Jeong Cha
J Pathol Transl Med. 2020;54(4):340-345.   Published online April 15, 2020
DOI: https://doi.org/10.4132/jptm.2020.03.18
  • 4,562 View
  • 122 Download
  • 8 Web of Science
  • 8 Crossref
AbstractAbstract PDF
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), is one of the specific type of low-grade B-cell lymphoma not infrequently found worldwide. It typically involves mucosal sites such as stomach and conjunctiva; however, primary hepatic MALT lymphoma has been extremely rarely reported. We describe a case of hepatic MALT lymphoma in a 70-year-old male patient who underwent left hepatectomy due to the incidentally detected liver masses at a medical checkup. The resected specimen revealed multinodular masses consisting of small-to-intermediate-sized lymphoid cells with serpentine pattern and focal lymphoepithelial lesions. The tumor cells were diffusely positive for CD20 and Bcl-2 but negative for CD3, CD10, CD5, CD23, CD43, and cyclinD1. The Ki-67 labeling index was 10% and immunoglobulin heavy chain gene rearrangement study confirmed monoclonal proliferation. In this paper, we discuss several unique clinicopathologic characteristics which will be helpful to the differential diagnosis of hepatic MALT lymphoma.

Citations

Citations to this article as recorded by  
  • “Speckled Enhancement” on Gd-EOB-DTPA Enhanced MR Imaging of Primary Hepatic Mucosa-associated Lymphoid Tissue Lymphoma
    Ryota Hyodo, Yasuo Takehara, Ayumi Nishida, Masaya Matsushima, Shinji Naganawa
    Magnetic Resonance in Medical Sciences.2023; 22(3): 273.     CrossRef
  • Primary hepatic extranodal marginal zone B-cell mucosa-associated lymphoid tissue lymphoma treated by laparoscopic partial hepatectomy: a case report
    Keisuke Okura, Satoru Seo, Hironori Shimizu, Hiroto Nishino, Tomoaki Yoh, Ken Fukumitsu, Takamichi Ishii, Koichiro Hata, Hironori Haga, Etsuro Hatano
    Surgical Case Reports.2023;[Epub]     CrossRef
  • Incidental Findings in Pediatric Patients: How to Manage Liver Incidentaloma in Pediatric Patients
    Andrius Cekuolis, Dagmar Schreiber-Dietrich, Rasa Augustinienė, Heike Taut, Judy Squires, Edda L. Chaves, Yi Dong, Christoph F. Dietrich
    Cancers.2023; 15(8): 2360.     CrossRef
  • Primary hepatic mucosa‐associated lymphoid tissue lymphoma: Case report and literature review
    Wing Yu Lau, Kit‐Man Ho, Fiona Ka‐Man Chan, Shi Lam, Kai‐Chi Cheng
    Surgical Practice.2022; 26(1): 56.     CrossRef
  • 18F-FDG Versus 68Ga-FAPI PET/CT in Visualizing Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
    Yizhen Pang, Long Zhao, Qihang Shang, Tinghua Meng, Haojun Chen
    Clinical Nuclear Medicine.2022; 47(4): 375.     CrossRef
  • Primary hepatopancreatobiliary lymphoma: Pathogenesis, diagnosis, and management
    Qianwen Wang, Kangze Wu, Xuzhao Zhang, Yang Liu, Zhouyi Sun, Shumei Wei, Bo Zhang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Positive effect of Bifidobacterium animalis subsp. lactis VHProbi YB11 in improving gastrointestinal movement of mice having constipation
    Hongchang Cui, Qian Wang, Congrui Feng, Chaoqun Guo, Jingyan Zhang, Xinping Bu, Zhi Duan
    Frontiers in Microbiology.2022;[Epub]     CrossRef
  • A case of primary hepatic extranodal marginal zone B-cell mucosa-associated lymphoid tissue (MALT) lymphoma treated by radiofrequency ablation (RFA), and a literature review
    Zhe Xu, Chong Pang, Jidong Sui, Zhenming Gao
    Journal of International Medical Research.2021; 49(3): 030006052199953.     CrossRef
Original Articles
Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
Ji Hye Kim, Kyungbin Kim, Misung Kim, Young Min Kim, Jae Hee Suh, Hee Jeong Cha, Hye Jeong Choi
J Pathol Transl Med. 2020;54(2):154-164.   Published online February 10, 2020
DOI: https://doi.org/10.4132/jptm.2019.11.13
  • 6,768 View
  • 158 Download
  • 14 Web of Science
  • 13 Crossref
AbstractAbstract PDF
Background
Immunomodulatory therapies targeting the interaction between programmed cell death protein 1 and programmed death-ligand 1 (PD-L1) have become increasingly important in anticancer treatment. Previous research on the subject of this immune response has established an association with tumor aggressiveness and a poor prognosis in certain cancers. Currently, scant information is available on the relationship between PD-L1 expression and gallbladder cancer (GBC).
Methods
We investigated the expression of PD-L1 in 101 primary GBC cases to determine the potential association with prognostic impact. PD-L1 expression was immunohistochemically assessed using a single PD-L1 antibody (clone SP263). Correlations with clinicopathological parameters, overall survival (OS), or progression- free survival (PFS) were analyzed.
Results
PD-L1 expression in tumor cells at cutoff levels of 1%, 10%, and 50% was present in 18.8%, 13.8%, and 7.9% of cases. Our study showed that positive PD-L1 expression at any cutoff was significantly correlated with poorly differentiated histologic grade and the presence of lymphovascular invasion (p < .05). PD-L1 expression at cutoff levels of 10% and 50% was significantly positive in patients with perineural invasion, higher T categories, and higher pathologic stages (p < .05). Additionally, there was a significant association noted between PD-L1 expression at a cutoff level of 50% and worse OS or PFS (p = .049 for OS, p = .028 for PFS). Other poor prognostic factors included histologic grade, T category, N category, pathologic stage, lymphovascular invasion, perineural invasion, growth pattern, and margin of resection (p < .05).
Conclusions
The expression of PD-L1 in GBC varies according to cutoff level but is valuably associated with poor prognostic parameters and survival. Our study indicates that the overexpression of PD-L1 in GBC had a negative prognostic impact.

Citations

Citations to this article as recorded by  
  • Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
    Giorgio Frega, Fernando P. Cossio, Jesus M. Banales, Vincenzo Cardinale, Rocio I. R. Macias, Chiara Braconi, Angela Lamarca
    Cells.2023; 12(16): 2098.     CrossRef
  • Gallbladder carcinomas: review and updates on morphology, immunohistochemistry, and staging
    Whayoung Lee, Vishal S. Chandan
    Human Pathology.2023; 132: 149.     CrossRef
  • Prognostic Relevance of PDL1 and CA19-9 Expression in Gallbladder Cancer vs. Inflammatory Lesions
    Neetu Rawal, Supriya Awasthi, Nihar Ranjan Dash, Sunil Kumar, Prasenjit Das, Amar Ranjan, Anita Chopra, Maroof Ahmad Khan, Sundeep Saluja, Showket Hussain, Pranay Tanwar
    Current Oncology.2023; 30(2): 1571.     CrossRef
  • Identification of genes associated with gall bladder cell carcinogenesis: Implications in targeted therapy of gall bladder cancer
    Ishita Ghosh, Ruma Dey Ghosh, Soma Mukhopadhyay
    World Journal of Gastrointestinal Oncology.2023; 15(12): 2053.     CrossRef
  • CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer
    Lu Cao, Kim R. Bridle, Ritu Shrestha, Prashanth Prithviraj, Darrell H. G. Crawford, Aparna Jayachandran
    International Journal of Molecular Sciences.2022; 23(3): 1565.     CrossRef
  • Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
    Sandra Kang, Bassel F. El-Rayes, Mehmet Akce
    Cancers.2022; 14(7): 1748.     CrossRef
  • Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer
    Chao Lv, Shukun Han, Baokang Wu, Zhiyun Liang, Yang Li, Yizhou Zhang, Qi Lang, Chongli Zhong, Lei Fu, Yang Yu, Feng Xu, Yu Tian
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series
    Sirui Tan, Jing Yu, Qiyue Huang, Nan Zhou, Hongfeng Gou
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma
    You-Na Sung, Sung Joo Kim, Sun-Young Jun, Changhoon Yoo, Kyu-Pyo Kim, Jae Hoon Lee, Dae Wook Hwang, Shin Hwang, Sang Soo Lee, Seung-Mo Hong
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer
    Thomas Albrecht, Fritz Brinkmann, Michael Albrecht, Anke S. Lonsdorf, Arianeb Mehrabi, Katrin Hoffmann, Yakup Kulu, Alphonse Charbel, Monika N. Vogel, Christian Rupp, Bruno Köhler, Christoph Springfeld, Peter Schirmacher, Stephanie Roessler, Benjamin Goep
    Cancers.2021; 13(7): 1682.     CrossRef
  • Immune Microenvironment in Gallbladder Adenocarcinomas
    Pallavi A. Patil, Kara Lombardo, Weibiao Cao
    Applied Immunohistochemistry & Molecular Morphology.2021; 29(8): 557.     CrossRef
  • Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
    Matteo Canale, Manlio Monti, Ilario Giovanni Rapposelli, Paola Ulivi, Francesco Giulio Sullo, Giulia Bartolini, Elisa Tiberi, Giovanni Luca Frassineti
    Cancers.2021; 13(22): 5671.     CrossRef
  • Overview of current targeted therapy in gallbladder cancer
    Xiaoling Song, Yunping Hu, Yongsheng Li, Rong Shao, Fatao Liu, Yingbin Liu
    Signal Transduction and Targeted Therapy.2020;[Epub]     CrossRef
The Role of TWIST in Ovarian Epithelial Cancers
Kyungbin Kim, Eun Young Park, Man Soo Yoon, Dong Soo Suh, Ki Hyung Kim, Jeong Hee Lee, Dong Hoon Shin, Jee Yeon Kim, Mee Young Sol, Kyung Un Choi
Korean J Pathol. 2014;48(4):283-291.   Published online August 26, 2014
DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.4.283
  • 7,053 View
  • 39 Download
  • 11 Crossref
AbstractAbstract PDF
Background

Epithelial-mesenchymal transition (EMT) is associated with tumor hypoxia. EMT is regulated, in part, by the action of TWIST, which inhibits of E-cadherin expression and may interfere with the p53 tumor-suppressor pathway.

Methods

We examined the expression of TWIST, E-cadherin, hypoxia-inducible factor 1α (HIF1α), and p53 by immunohistochemistry in 123 cases of ovarian epithelial cancers (OEC) to evaluate the role of TWIST in OEC. We assessed the association between protein expression and clinicopathologic parameters.

Results

The expression of TWIST, E-cadherin, HIF1α, and p53 proteins was found in 28.5%, 51.2%, 35.0%, and 29.3% of cases, respectively. TWIST expression was associated with higher histologic grade and unfavorable survival. TWIST expression was correlated with HIF1α expression and reduced E-cadherin expression. The altered HIF1α/TWIST/E-cadherin pathway was associated with lower overall survival (OS), while the co-expression of TWIST and p53 was correlated with lower progression-free survival. In the multivariate analyses, TWIST expression was an independent prognostic factor for OS.

Conclusions

Our data imply that TWIST expression could be a useful predictor of unfavorable prognosis for OEC. TWIST may affect the p53 tumor-suppressor pathway. Moreover, hypoxia-mediated EMT, which involves the HIF1α/TWIST/E-cadherin pathway may play an important role in the progression of OEC.

Citations

Citations to this article as recorded by  
  • E-Cadherin Expression in Relation to Clinicopathological Parameters and Survival of Patients with Epithelial Ovarian Cancer
    Michal Kielbik, Izabela Szulc-Kielbik, Magdalena Klink
    International Journal of Molecular Sciences.2022; 23(22): 14383.     CrossRef
  • Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer
    Danchen Wu, Asish Dasgupta, Austin D. Read, Rachel E.T. Bentley, Mehras Motamed, Kuang-Hueih Chen, Ruaa Al-Qazazi, Jeffrey D. Mewburn, Kimberly J. Dunham-Snary, Elahe Alizadeh, Lian Tian, Stephen L. Archer
    Free Radical Biology and Medicine.2021; 170: 150.     CrossRef
  • Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancers: HIF-1α and Beyond
    Shing Yau Tam, Vincent W. C. Wu, Helen K. W. Law
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Expression of selected epithelial–mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers
    Pawel Sadlecki, Jakub Jóźwicki, Paulina Antosik, Marek Grabiec
    Tumor Biology.2018; 40(6): 101042831878480.     CrossRef
  • Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer
    In Hye Song, Kyu-Rae Kim, Sehun Lim, Seok-Hyung Kim, Chang Ohk Sung
    Pathology - Research and Practice.2018; 214(10): 1564.     CrossRef
  • Transcription factors controlling E-cadherin down-regulation in ovarian cancer
    Holly Russell, Md Zahidul Islam Pranjol
    Bioscience Horizons: The International Journal of Student Research.2018;[Epub]     CrossRef
  • Immunohistochemical expression of TWIST in oral squamous cell carcinoma and its correlation with clinicopathologic factors
    Maryam Seyedmajidi, Safoura Seifi, Dariush Moslemi, Seyyedeh-Fatemeh Mozaffari, Hemmat Gholinia, Zahra Zolfaghari
    Journal of Cancer Research and Therapeutics.2018; 14(5): 964.     CrossRef
  • Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF‐κB‐mediated IKKβ expression
    Yi‐Hui Wu, Yu‐Fang Huang, Tzu‐Hao Chang, Cheng‐Yang Chou
    International Journal of Cancer.2017; 141(11): 2305.     CrossRef
  • MicroRNA-219-5p inhibits the proliferation, migration, and invasion of epithelial ovarian cancer cells by targeting the Twist/Wnt/β-catenin signaling pathway
    Chunyan Wei, Xi Zhang, Sai He, Bianli Liu, Hongfang Han, Xuejun Sun
    Gene.2017; 637: 25.     CrossRef
  • Inhibition of proliferation and invasion of hepatocellular carcinoma cells by lncRNA-ASLNC02525 silencing and the mechanism
    Zi Chen, Dongwen Xu, Tao Zhang
    International Journal of Oncology.2017; 51(3): 851.     CrossRef
  • Is overexpression of TWIST, a transcriptional factor, a prognostic biomarker of head and neck carcinoma? Evidence from fifteen studies
    Xianlu Zhuo, Huanli Luo, Aoshuang Chang, Dairong Li, Houyu Zhao, Qi Zhou
    Scientific Reports.2015;[Epub]     CrossRef
Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers
Kyungbin Kim, Won Young Park, Jee Yeon Kim, Mee Young Sol, Dong Hun Shin, Do Youn Park, Chang Hun Lee, Jeong Hee Lee, Kyung Un Choi
Korean J Pathol. 2012;46(6):532-540.   Published online December 26, 2012
DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.6.532
  • 8,047 View
  • 38 Download
  • 13 Crossref
AbstractAbstract PDF
Background

Tumor hypoxia is associated with malignant progression and treatment resistance. Hypoxia-related factors, such as carbonic anhydrase IX (CA IX), glucose transporter-1 (GLUT-1), and vascular endothelial growth factor (VEGF) permit tumor cell adaptation to hypoxia. We attempted to elucidate the correlation of these markers with variable clinicopathological factors and overall prognosis.

Methods

Immunohistochemistry for CA IX, GLUT-1, and VEGF was performed on formalin-fixed, paraffin-embedded tissues from 125 cases of ovarian epithelial cancer (OEC).

Results

CA IX expression was significantly associated with an endometrioid and mucinous histology, nuclear grade, tumor necrosis, and mitosis. GLUT-1 expression was associated with tumor necrosis and mitosis. VEGF expression was correlated only with disease recurrence. Expression of each marker was not significant in terms of overall survival in OECs; however, there was a significant correlation between poor overall survival rate and high coexpression of these markers.

Conclusions

The present study suggests that it is questionable whether CA IX, GLUT-1, or VEGF can be used alone as independent prognostic factors in OECs. Using at least two markers helps to predict patient outcomes in total OECs. Moreover, the inhibition of two target gene combinations might prove to be a novel anticancer therapy.

Citations

Citations to this article as recorded by  
  • Effect of Ultrasound Therapy at the ST11 on Sympathetic Nervous System Change: A Prospective Randomized Controlled Study
    Shinwoo Kang, Dongho Keum
    Journal of Korean Medicine Rehabilitation.2023; 33(4): 167.     CrossRef
  • A systematic review verified by bioinformatic analysis based on TCGA reveals week prognosis power of CAIX in renal cancer
    Zikuan Zhang, Bo Wu, Yuan Shao, Yongquan Chen, Dongwen Wang, Lucia Magnelli
    PLOS ONE.2022; 17(12): e0278556.     CrossRef
  • Effect of Acupuncture at the Field of the Auricular Branch of the Vagus Nerve on Autonomic Nervous System Change
    Sunjoo An, Dongho Keum
    Journal of Korean Medicine Rehabilitation.2021; 31(2): 81.     CrossRef
  • Responses of Autonomic Nervous System and Gastrointestinal Function to Acupuncture at Abdominal Anterior Cutaneous Nerve : A Pilot Study
    Seohyun Park, Hojun Kim, Dongho Keum
    Journal of Korean Medicine.2019; 40(1): 99.     CrossRef
  • Omega-3 polyunsaturated fatty acid docosahexaenoic acid and its role in exhaustive-exercise-induced changes in female rat ovulatory cycle
    Abeer F. Mostafa, Shereen M. Samir, R.M. Nagib
    Canadian Journal of Physiology and Pharmacology.2018; 96(4): 395.     CrossRef
  • Clear cell carcinomas of the ovary and kidney: clarity through genomics
    Jennifer X Ji, Yi Kan Wang, Dawn R Cochrane, David G Huntsman
    The Journal of Pathology.2018; 244(5): 550.     CrossRef
  • Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
    Simon J. A. van Kuijk, Ala Yaromina, Ruud Houben, Raymon Niemans, Philippe Lambin, Ludwig J. Dubois
    Frontiers in Oncology.2016;[Epub]     CrossRef
  • Review of Research Topics on Abdominal Examination
    Jihye Kim, Jeong Hwan Park, Keun Ho Kim
    Journal of Korean Medicine.2016; 37(3): 1.     CrossRef
  • Expression of hypoxic markers and their prognostic significance in soft tissue sarcoma
    JEUNG IL KIM, KYUNG UN CHOI, IN SOOK LEE, YOUNG JIN CHOI, WON TACK KIM, DONG HOON SHIN, KYUNGBIN KIM, JEONG HEE LEE, JEE YEON KIM, MEE YOUNG SOL
    Oncology Letters.2015; 9(4): 1699.     CrossRef
  • Evaluation of a Hypoxia Regulated Gene Panel in Ovarian Cancer
    Amanda F. Baker, Scott W. Malm, Ritu Pandey, Cindy Laughren, Haiyan Cui, Denise Roe, Setsuko K. Chambers
    Cancer Microenvironment.2015; 8(1): 45.     CrossRef
  • Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy
    MICHAL PASTOREK, VERONIKA SIMKO, MARTINA TAKACOVA, MONIKA BARATHOVA, MARIA BARTOSOVA, LUBA HUNAKOVA, OLGA SEDLAKOVA, SONA HUDECOVA, OLGA KRIZANOVA, FRANCK DEQUIEDT, SILVIA PASTOREKOVA, JAN SEDLAK
    International Journal of Oncology.2015; 47(1): 51.     CrossRef
  • Overexpression of Glucose Transporter-1 (GLUT-1) Predicts Poor Prognosis in Epithelial Ovarian Cancer
    Hanbyoul Cho, You Sun Lee, Julie Kim, Joon-Yong Chung, Jae-Hoon Kim
    Cancer Investigation.2013; 31(9): 607.     CrossRef
  • Towards Lipidomics of Low-Abundant Species for Exploring Tumor Heterogeneity Guided by High-Resolution Mass Spectrometry Imaging
    Jonathan Cimino, David Calligaris, Johann Far, Delphine Debois, Silvia Blacher, Nor Sounni, Agnès Noel, Edwin De Pauw
    International Journal of Molecular Sciences.2013; 14(12): 24560.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine